Please assess the completion status of the following clinical trial:

Trial Title: PF-00489791 For The Treatment Of Raynaud's

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Active Raynaud's Phenomenon~* Stable disease and medication requirements over the previous two months~* For Secondary Raynaud's Phenomenon subjects, a diagnosis of scleroderma using the American College of Rheumatology criteria or by the presence of at least 3/5 features of CREST syndrome~* both sexes~Exclusion Criteria:~* Uncontrolled hypertension, diabetes mellitus, angina, or using oral nitrates~* Smoking within 3 months or smoking cessation using nicotine products~* Subjects currently taking sildenafil, tadalafil or vardenafil~* Subjects with ulnar arterial occlusive disease as shown by a modified Allen test~* Pregnant or breast feeding or considering pregnancy in next 4 months~* Participation in trial for investigational drug within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Secondary Raynaud 4 mg dose (period 1) (Type: EXPERIMENTAL): None
- Secondary Raynaud 4 mg dose (period 2) (Type: EXPERIMENTAL): None
- Secondary Raynaud 20 mg dose (period 1) (Type: EXPERIMENTAL): None
- Secondary Raynaud 20 mg dose (period 2) (Type: EXPERIMENTAL): None
- Primary Raynaud 4 mg dose (period 1) (Type: EXPERIMENTAL): None
- Primary Raynaud 4 mg dose (period 2) (Type: EXPERIMENTAL): None
- Primary Raynaud 20 mg dose (period 1) (Type: EXPERIMENTAL): None
- Primary Raynaud 20 mg dose (period 2) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).